Evidence map›Paper›PMID 25996128›Full record

ArticleNeuron2015

Using opioid receptors to expand the chemogenetic and optogenetic toolbox.

Diane M Damez-Werno, Paul J Kenny

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Neuron, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Diane M Damez-WernoDepartment of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-6574, USA.
Paul J KennyDepartment of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-6574, USA. Electronic address: paul.kenny@mssm.edu.
Icahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Neuron, innovative new modifications to opioid receptors are used to expand the tools available to modulate neuronal activity. Vardy et al. (2015) describe a new "DREADD" chemogenetic tool based on the inhibitory κ opioid receptor (KORD) that can be used in conjunction with already-available DREADDs. Siuda et al. (2015) report the development of "opto-MOR," a light-activatable μ opioid receptor (MOR) chimera that can be used to better understand the complexities of MOR signaling.

Indexed as

OptogeneticsAnalgesics, OpioidAnimalsBehavior, AnimalDiterpenesGABAergic NeuronsNeuronsReceptors, Opioid, kappaReceptors, Opioid, muSignal TransductionAnalgesics, OpioidDiterpenesReceptors, Opioid, kappaReceptors, Opioid, mu

Identifiers

PMID25996128
OpenAlexW1533016149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.